Ken Griffin Spring Works Therapeutics, Inc. Transaction History

Citadel Advisors LLC

$559 Billion
Q4 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Spring Works Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 3,400 shares of SWTX stock, worth $164,696. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,400

Previous 8,800 61.36%

Holding current value

$164,696

Previous $281,000 56.58%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$28.61 - $42.55 $6.94 Million - $10.3 Million	242,525 Added 185.55%	373,231 $13.5 Million
Q3 2024 Nov 14, 2024	BUY	$32.04 - $42.76 $1.05 Million - $1.4 Million	32,755 Added 33.44%	130,706 $4.19 Million
Q2 2024 Aug 14, 2024	SELL	$36.06 - $47.62 $22.1 Million - $29.2 Million	-612,316 Reduced 86.21%	97,951 $3.69 Million
Q1 2024 May 15, 2024	BUY	$36.5 - $52.5 $10.7 Million - $15.4 Million	292,453 Added 70.0%	710,267 $35 Million
Q4 2023 Feb 14, 2024	BUY	$18.94 - $37.24 $7.51 Million - $14.8 Million	396,508 Added 1861.02%	417,814 $15.3 Million
Q3 2023 Nov 14, 2023	BUY	$23.12 - $31.38 $305,762 - $415,000	13,225 Added 163.66%	21,306 $492,000
Q2 2023 Aug 14, 2023	SELL	$23.15 - $32.71 $598,936 - $846,273	-25,872 Reduced 76.2%	8,081 $211,000
Q1 2023 May 15, 2023	SELL	$24.97 - $34.05 $2.32 Million - $3.17 Million	-92,993 Reduced 73.25%	33,953 $873,000
Q4 2022 Feb 14, 2023	SELL	$21.73 - $28.72 $870,264 - $1.15 Million	-40,049 Reduced 23.98%	126,946 $3.3 Million
Q3 2022 Nov 14, 2022	BUY	$24.1 - $39.66 $905,678 - $1.49 Million	37,580 Added 29.04%	166,995 $4.77 Million
Q2 2022 Aug 15, 2022	BUY	$18.36 - $60.07 $1.88 Million - $6.16 Million	102,516 Added 381.11%	129,415 $3.19 Million
Q1 2022 May 16, 2022	SELL	$48.97 - $65.46 $1.34 Million - $1.79 Million	-27,283 Reduced 50.35%	26,899 $1.52 Million
Q4 2021 Feb 14, 2022	SELL	$53.3 - $75.84 $6.29 Million - $8.95 Million	-117,954 Reduced 68.52%	54,182 $3.36 Million
Q3 2021 Nov 15, 2021	SELL	$62.66 - $88.26 $40.1 Million - $56.5 Million	-639,889 Reduced 78.8%	172,136 $10.9 Million
Q2 2021 Aug 16, 2021	BUY	$67.45 - $85.63 $717,263 - $910,589	10,634 Added 1.33%	812,025 $66.9 Million
Q1 2021 May 17, 2021	BUY	$65.1 - $93.59 $560,185 - $805,341	8,605 Added 1.09%	801,391 $59 Million
Q4 2020 Feb 16, 2021	BUY	$48.36 - $77.92 $1.65 Million - $2.67 Million	34,207 Added 4.51%	792,786 $57.5 Million
Q3 2020 Nov 16, 2020	SELL	$36.14 - $51.99 $6 Million - $8.64 Million	-166,102 Reduced 17.96%	758,579 $36.2 Million
Q2 2020 Aug 14, 2020	SELL	$22.98 - $48.57 $427,749 - $904,081	-18,614 Reduced 1.97%	924,681 $38.8 Million
Q1 2020 May 15, 2020	BUY	$20.44 - $41.21 $253,987 - $512,075	12,426 Added 1.33%	943,295 $25.5 Million
Q4 2019 Feb 14, 2020	SELL	$17.74 - $39.52 $6.97 Million - $15.5 Million	-392,948 Reduced 29.68%	930,869 $35.8 Million
Q3 2019 Nov 14, 2019	BUY	$18.8 - $27.82 $24.9 Million - $36.8 Million	1,323,817 New	1,323,817 $28.7 Million

Others Institutions Holding SWTX

# of Institutions

236

Shares Held

67.2M

Call Options Held

260K

Put Options Held

316K

View Full List

About SpringWorks Therapeutics, Inc.

Ticker SWTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,401,100
Market Cap $3.02B
Description
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...

More about SWTX

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account